Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZOM
CUSIPN/A
Phone734-369-2555
Debt
Debt-to-Equity RatioN/A
Current Ratio3.25
Quick Ratio3.25
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.05 per share
Price / Book41.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees20
Outstanding Shares94,510,000
Market Cap$176.74 million
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."
How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?
When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?
Are investors shorting Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,196,704 shares, a decrease of 12.9% from the August 15th total of 1,373,756 shares. Based on an average daily trading volume, of 31,135 shares, the days-to-cover ratio is currently 38.4 days. Currently, 2.8% of the shares of the stock are short sold. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s Current Options Chain.
Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?
Some companies that are related to Zomedica Pharmaceuticals Corp (NYSEAMERICAN) include Insys Therapeutics (INSY), Dova Pharmaceuticals (DOVA), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Obseva (OBSV), Kura Oncology (KURA), Verastem (VSTM), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), Basilea Pharmaceutica (BPMUF), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), ChemoCentryx (CCXI), OptiNose (OPTN) and Beyondspring (BYSI).
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the folowing people:
- Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
- Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
- Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
- Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
- Mr. Bruk Herbst, Chief Commercial Officer (Age 49)
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (12.78%), BlackRock Inc. (1.67%), Schwab Charles Investment Management Inc. (0.08%), Bank of New York Mellon Corp (0.08%), Bank of New York Mellon Corp (0.08%) and Northern Trust Corp (0.07%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Rodney James Williams. View Institutional Ownership Trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).
Which major investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock?
How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?
One share of ZOM stock can currently be purchased for approximately $2.05.
How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $176.74 million. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) employs 20 workers across the globe.
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?
How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]
MarketBeat Community Rating for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE ZOM)
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
